Abstract:Alcohol-associated liver disease (ALD) is the most common cause of advanced hepatic disease and frequent indication for liver transplantation worldwide. With harmful alcohol use as the primary risk factor, increasing alcohol use over the past decade has resulted in rapid growth of the ALD-related healthcare burden. The spectrum of ALD ranges from early asymptomatic liver injury to advanced disease with decompensation and portal hypertension. Compared with those with other etiologies of liver disease, patients with ALD progress faster and more often present at an advanced stage. A unique phenotype of advanced disease is alcohol-associated hepatitis (AH) presenting with rapid onset or worsening of jaundice, and acute on chronic liver failure in severe forms conveying a 1-month mortality risk of 20%–50%. The model for end stage disease score is the most accurate score to stratify AH severity (>20 defined as severe disease). Corticosteroids are currently the only available therapeutic with proven efficacy for patients with severe AH, providing survival benefit at 1 month in 50%–60% of patients. Abstinence of alcohol use, a crucial determinant of long-term outcomes, is challenging to achieve in ALD patients with concurrent alcohol use disorder (AUD). As patients with ALD are rarely treated for AUD, strategies are needed to overcome barriers to AUD treatment in patients with ALD and to promote a multidisciplinary integrated care model with hepatology, addiction medicine providers, and social workers to comprehensively manage the dual pathologies of liver disease and of AUD. Liver transplantation, a definitive treatment option in patients with advanced cirrhosis, should be considered in selected patients with AH, who are unresponsive to medical therapy and have a low risk of relapse to posttransplant alcohol use. Level of evidence and strength of recommendations were evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations system. This guideline was developed under the American College of Gastroenterology Practice Parameters Committee.

Current Medical Treatment for Alcohol-Associated Liver Disease

Current and future treatment for alcoholic‐related liver diseases

Pharmacotherapy of alcoholic liver disease in clinical practice

Alcohol-associated liver disease - a current overview

Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy

Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases

ACG Clinical Guideline: Alcohol-Associated Liver Disease

Treatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action

Alcohol use disorder in community management of chronic liver diseases

Emerging Pharmacologic Treatments for Alcohol-Associated Hepatitis: Current Status and Future Landscape

Alcoholic Hepatitis: A Review

Emerging Pharmacotherapies in Alcohol-Associated Hepatitis

Guidelines of prevention and treatment for alcoholic liver disease (2018, China).

Alcohol or Gut Microbiota: Who Is the Guilty?

Nutritional and microbiota-based therapeutic intervention for alcohol-associated liver disease: Pathogenesis to therapeutic insights

Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting

Targeting Inflammation for the Treatment of Alcoholic Liver Disease.

Current Pharmacotherapy and Nutrition Therapy of Alcohol-Associated Liver Disease

New Drug Targets for Alcoholic Liver Disease

Effect of Low-Dose Alcohol Consumption on Chronic Liver Disease

Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease